GlassScriptPhysician profile
Kelsey Rose Duncan
NPI 1679004618
$2,231.16
in general payments reported to CMS, 2019-2025
14 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.92 · 2021: $16.60 · 2022: $38.72 · 2023: $247 · 2024: $231 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,226 · Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,225.59 |
| Food and Beverage | $858.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,232.49 | 2025 | Penumbra System |
| Stryker Corporation | $190.89 | 2024-2025 | Target, Fixos |
| Medtronic, INC. | $173.61 | 2023-2024 | Pipeline |
| Contego Medical, INC | $121.63 | 2024 | |
| Abbvie INC. | $112.64 | 2023 | Qulipta, Ubrelvy |
| Microvention, INC. | $100.55 | 2025 | Stent, Web Aneurysm Embolization System |
| Acorda Therapeutics, INC | $91.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $62.03 | 2022-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $41.48 | 2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $26.17 | 2024 | Inbrija, Xeomin |
| Lundbeck LLC | $21.97 | 2025 | Vyepti |
| Neurelis, INC. | $21.19 | 2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2025 | Austedo Xr |
| Celgene Corporation | $16.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.